<DOC>
	<DOCNO>NCT02604238</DOCNO>
	<brief_summary>The primary aim study evaluate whether mid dose ( safe dose ) Alteplase addition standard treatment heparin ( LMWH ) patient pulmonary embolism ( PE ) intermediate risk , effective reduce : - right ventricular dysfunction - pulmonary hypertension 24 hour 7 day treatment - PE recurrence 7days 30 day treatment without increase incidence bleed intra-extracranial</brief_summary>
	<brief_title>Efficacy Safety Half Dose Alteplase Added Heparine , Patients With Moderate Pulmonary Embolism</brief_title>
	<detailed_description>The guideline European Society Cardiology ( ESC2014 ) confirm indication pharmacological revascularization thrombolysis case pulmonary embolism high risk thus hemodynamically unstable ( class recommendation I , level evidence B ) , reserve surgical interventional procedure case thrombolysis fail contraindicate , remain controversial role thrombolysis patient pulmonary embolism intermediate risk ; current state , EP intermediate risk , standard treatment involve administration low molecular weight heparin ( LMWH ) , fondaparinux ( 5-10 day follow anticoagulation therapy vitamin K antagonist ) alternatively new anticoagulant oral ( NAO ) . Although result study PEITHO , recently publish , confirm indication thrombolytic therapy primary reperfusion patient embolism pulmonary high risk provide element reflection incidence intracranial hemorrhage major , recent study suggest thrombolysis tPA reduce dose ( half dose use standard thrombolysis ) addition anticoagulant ( low molecular weight heparin ) may reduce pulmonary hypertension ( systolic artery pulmonary pressure &gt; 40 mmHg ) incidence recurrent PE . In protocol , base study MOPETT pharmacokinetic data available , use `` safe dose '' ( safe dose reduce ) alteplase provide intravenous ( iv ) bolus load dose 10 mg 1 min , follow intravenous infusion 40 mg within two hour ( patient weigh &lt; 50 kg load dose iv bolus 0.5 mg 1 min , follow iv infusion 40 mg within two hour ) . After treatment alteplase , heparin therapy resume aPTT value less twice upper limit normal ; infusion adjust maintain aPTT 50-70 second ( 1.5 2.5 time reference value ) , safety reason exclude patient &gt; 65 -70 year ( increase risk bleed complication relate age comorbidities ) .</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1. pulmonary embolism intermediate risk define Guidelines ESC2014 [ document pulmonary CT angiography ] 2. pulmonary hypertension ( systolic pulmonary pressure great equal 40 mm Hg ) [ document echocardiogram presence thrombotic material rightsided ] 3. disfunction Ventricular right confirm echocardiogram TC chest : dilation right section ( &gt; 30 mm parasternal relationship right ventricle/left ventricle &gt; 1 ) paradoxical movement interventricular septum TAPSE reduce ( Tricuspid Annular Plane Systolic Excursion ) tricuspid regurgitation gradient VD/AD &gt; 30 mmHg , absence right ventricular hypertrophy , McConnell sign ( apical segment free wall right ventricle normalKinetic hyperkinetic hypokinesia akinesia remain part right ventricular wall ) , 4. myocardial damage confirm : Troponin I T positive higt value biomarkers myocardial damage : BNP NTproBNP 5. inform consent 1. age &lt; 18 year &gt; 65 year 2 . HASBLED score ≥ 3 ( 23 ) 3. intracranial tumor 4. ischemic stroke within 2 month 5. surgery neurological within 1 month surgery within 10 day 6. trauma within 15 day 7. hypotension hospitalization ( systemic blood pressure &lt; 90 mmHg ) 8. uncontrolled hypertension ( SBP &gt; 180mmHg PAD &gt; 110mmHg ) 9. clot disorder 10. thrombocytopenia ( &lt; 100.000 ) 11. platelet count 100 × 109 /L severe thrombocytopenia ( platelet count &lt; 50.000 ptl / mm3 ) 12. liver failure 13. kidney failure 14. gastrointestinal bleeding within 10 day 15. pregnancy childbirth within 30 day 16. contraindication use thrombolytic 17. contraindication use low molecular weight heparin ( enoxaparin ) 18. anticoagulation therapy start 8 hour 19 . COPD 20. endocarditis 21. severe obesity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Pulmonary Embolism intermediate risk</keyword>
</DOC>